Shedding Light On Cancer Cells
Posted on: Thursday, 24 September 2009, 09:40 CDT
Scientists label cells with colored or glowing chemicals to observe how basic cellular activities differ between healthy and cancerous cells. Existing techniques for labeling cells are either too slow or too toxic to perform on live cells. Now, a study reviewed by Philip Dawson, a member of Faculty of 1000 Biology and leading authority in chemistry and cell biology, describes a novel labeling technique that uses a chemical reaction to make live cancer cells light up quickly and safely.
Researchers at Massachusetts General Hospital developed a two-step process to specifically tag cancer cells. First, chemically modified antibodies home in on cancer cells. Then a chemical reaction called cycloaddition transfers a dye onto the antibody making the cancer cells glow when viewed through a microscope.
The novel cycloaddition reaction is fast, very specific, and requires minimal manipulation of the cells. Dawson comments that, in combining antibody binding with the cycloaddition, "low signal-to-noise ratios are achieved". This new labeling technique could be used to track the location and activity of anti-cancer drugs, the location of cancer-specific proteins within the cell, or to visualize cancer cells inside a living organism.
Dawson concludes that cycloaddition will allow scientists to observe live cancer cells in the body, leading to a better understanding of cancer's basic processes.
---
On the Net:
Related Articles
- FDA approves GlaxoSmithKline's VOTRIENT(TM) for advanced renal cell cancer
- ZymoGenetics Presents Interim IL-21 Phase 2 Results in Renal Cell Cancer
- ZymoGenetics Initiates Phase II Renal Cell Cancer Trial
- ZymoGenetics Begins Phase 2 Trial in Renal Cell Cancer Evaluating IL-21 Combined With Nexavar(R)
- Cytokinetics Announces Initiation of Phase II Clinical Trial in Renal Cell Cancer and Phase I Clinical Trial in Pediatric Solid Tumors
- ZymoGenetics Presents Results From Two Atacicept Phase 1b Clinical Trials in B-Cell Cancer
- ZymoGenetics Begins Phase 1/2 Clinical Trial With IL-21 and Nexavar in Patients With Renal Cell Cancer
- Dendreon Presents Data at American Association of Immunology Conference Highlighting Potential New Active Immunotherapy for Treatment of Renal Cell Cancer
- New In Vitro Study of GlycoGenesys' GCS-100LE Yields Promising Data in Chronic Lymphocytic Leukemia and Other B-Cell Cancers
- Pro: Greater Funding of Cell and Molecular Biology Has Delivered What Was Promised to Respiratory Medicine
 |
 |
User Comments (0)
RSS Feeds